From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Catalent, Inc.
TypePublic company
PredecessorCardinal Health PTS
HeadquartersSomerset, New Jersey, U.S.
Number of locations
49 (2020)[1]
Key people
John Chiminski
(Chair, CEO),
Alessandro Maselli
(President, COO),
Thomas Castellano
(Senior Vice President, CFO)
ServicesDrug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
RevenueUS$3.09 billion (2020)[1]
US$394.4 million (2020)[1]
US$220.7 million (2020)[1]
Number of employees
14,000 (2020)

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people,[2] including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.[1]

Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc.[3] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[4]

In 2014, Catalent became a public company and is listed on the New York Stock Exchange.


Before 2007[edit]

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[5] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[6]

In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[7] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[8] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[5] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[8]

In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[5] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[5] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[5]

From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions.[5]

Formation of Catalent in 2007[edit]

In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[3]

After 2007 and initial public offering[edit]

In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[9] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[7][10][11] In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.[12]

Catalent announced its initial public offering in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[13] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT.[13]

In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[14] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[14]

In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[15] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.[16] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.[17] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.[18]

Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.[19] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment.[20] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[21]

In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities.[22] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer.[23] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition.[24]

In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.[25]

In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[26] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.[27][28]

In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[29] AstraZeneca,[30] and Moderna[31] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.[32][33] In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.[34] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's St. Petersburg facility.[35] Also in 2021, Catalent acquired German gene therapy development firm Rheincell Theraputics.[36]

In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form.[37]


Annual Financial Table[1]
# 2016 2017 2018 2019 2020
Sales/Revenue 1.85B 2.08B 2.46B 2.52B 3.09B
Total Current Assets 3.09B 2.45B 4.53B 6.18B 7.78B
Net Operating Cash Flow 155.3M 299.5M 374.5M 247.7M 440.3M


  1. ^ a b c d e f "Catalent 2020 Annual Report" (PDF). Catalent Investors. Retrieved 23 February 2021.
  2. ^ "Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency". BioSpace. Retrieved 8 November 2020.
  3. ^ a b "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
  4. ^ "Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock". The Wall Street Journal. 19 May 1998. Retrieved 2 December 2019.
  5. ^ a b c d e f "Cardinal Health's timeline --". Archived from the original on 11 April 2015. Retrieved 7 April 2015.
  6. ^ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
  7. ^ a b "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
  8. ^ a b Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
  9. ^ "Catalent completes Aptuit deal". 20 February 2012. Retrieved 7 April 2015.
  10. ^ Wasserman, Robert (8 September 2016). "2 big companies and 1 small one to target in the pharma/biotech space". TheStreet. Retrieved 9 July 2019.
  11. ^ "Gelita and R.P. Scherer End 60 Year Joint Venture". Retrieved 9 July 2019.
  12. ^ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". Retrieved 7 April 2015.
  13. ^ a b "Catalent Issues Initial Public Offering" (8). Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
  14. ^ a b "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". Pharmtech.
  15. ^ "Catalent out-licenses ADC to Triphase". BioPharma Dive. Retrieved 4 October 2019.
  16. ^ "Catalent Buys Pharmatek and Lands Spray Drying Technology". Pharmaceutical Investing News. 14 September 2016.
  17. ^ "Catalent targets biologics with Cook Pharmica acquisition". Pharmaceutical Commerce. 19 September 2017. Retrieved 21 November 2019.
  18. ^ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals". FiercePharma. Retrieved 16 August 2019.
  19. ^ "Catalent Names Alessandro Maselli President and Chief Operating Officer". Retrieved 19 February 2019.
  20. ^ "Catalent Invests in Zydis Ultra Commercialization".
  21. ^ "Wellness products take off in the growing recreational cannabis market". Marijuana Business Magazine. 1 October 2019. Retrieved 9 December 2019.
  22. ^ Hopkins, Kimberly Chin and Jared S. "Catalent to Buy Paragon Bioservices for $1.2 Billion". WSJ. Retrieved 1 November 2019.
  23. ^ "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies". FiercePharma. Retrieved 26 November 2019.
  24. ^ "Paragon growing quickly toward 1,000 employees after Catalent acquisition". Baltimore Business Journal. 17 October 2019. Retrieved 23 December 2019.
  25. ^ "'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops". Endpoints News. Retrieved 18 October 2019.
  26. ^ "Bristol-Myers offloads manufacturing plant to Catalent". Outsourcing-Pharma. 13 January 2020.
  27. ^ "Catalent laying out $315M to snatch another gene therapy CDMO". FiercePharma. Retrieved 3 February 2020.
  28. ^ "Catalent adds to regenerative therapy portfolio with $315m acquisition". Manufacturing Chemist. 3 February 2020.
  29. ^ "Pfizer to outsource some drug production, focus on coronavirus vaccine". CNBC. 9 May 2020. Retrieved 16 June 2020.
  30. ^ "AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine". The New York Times. 15 June 2020. Retrieved 16 June 2020.
  31. ^ "Moderna Is the Latest Coronavirus Vaccine Partner for Catalent". Barrons. Retrieved 7 July 2020.
  32. ^ "'Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus". The Wall Street Journal. 27 May 2020. Retrieved 16 June 2020.
  33. ^ "Vaccine makers face biggest medical manufacturing challenge in history". Reuters. 25 June 2020.
  34. ^ "AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland". Baltimore Business Journal. 26 August 2020. Retrieved 24 September 2020.
  35. ^ "Manufacturer to help develop potential Covid treatment at St. Pete facility". Tampa Bay Business Journal. Retrieved 17 July 2020.
  36. ^ "Catalent Finalizes RheinCell Therapeutics Acquisition". BioPharm International. 6 August 2021.
  37. ^ Hopkins, Jared S. (30 August 2021). "WSJ News Exclusive | Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved 30 August 2021.